The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.

摘要: // Saber Imani 1, 2 , Xianqin Zhang 1 Hossein Hosseinifard 3 Shangyi Fu 4 Junjiang Key Laboratory of Epigenetics and Oncology, The Research Center for Precision Medicine, Southwest Medical University, Luzhou, Sichuan, PR China Chemical Injuries Center, Baqiyatallah Sciences University (BMSU), Tehran, Iran Evidence Based Medicine (RCEBM), Tabriz Sciences, Tabriz, Honors College, Houston, TX, USA Correspondence to: Fu, email: fujunjiang@swmu.edu.cn fujunjiang@hotmail.com Keywords: breast cancer, microRNA-34a, biomarker, diagnostics, meta-analysis Received: November 18, 2016      Accepted: January 30, 2017      Published: February 20, 2017 ABSTRACT Background: MicroRNA-34a (miR-34a) is a master regulator tumor suppression in cancer (BC). This systematic review aims to analyze the diagnostic accuracy miR-34a detection BC as biomarker. Results: A total 1858 cases 494 controls from thirteen eligible studies reported 9 publications were included. overall pooled sensitivity, specificity, negative likelihood ratio (NLR), positive (PLR), odds (DOR) 85.50% (95% CI: 83.80-87.00%), 70.00% 65.80–74.10%), 0.29 0.19–0.43), 2.58 1.91–3.43), 9.39 5.47–16.12), respectively. Similarly, area under curve (AUC) summary receiver operating characteristic (SROC) was 0.80, indicating high conservation Furthermore, subgroup analysis suggested that use biomarker more accurate tissue-based sample invasive BC. We also indicated capable diagnosing people Caucasian descent. Materials Methods: search conducted address expression level noncancerous controls. Diagnostic capacity assessed using sensitivity DOR, AUC SROC. PLR NLR verified estimate clinical level. quality included by QUADAS-2. Conclusions: These findings suggest promising non-invasive Well-designed cohort should be implemented warrant value purposes.